Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
X-TROZINE L.A. vs ACTIFED
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Hypertension (extended-release formulation),Off-label: Management of opioid withdrawal symptoms
Temporary relief of symptoms associated with allergic rhinitis (sneezing, rhinorrhea, pruritus),Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
250 mg orally once daily. May be increased to 500 mg once daily if needed.
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min).
Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (p H-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours.
Primarily hepatic via CYP3A4; metabolites include inactive glucuronides.
Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%).
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine.
95-98% bound to albumin and alpha-1-acid glycoprotein.
Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin).
0.8-1.2 L/kg, indicating extensive tissue distribution.
Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution.
Oral: 40-60% (due to first-pass metabolism); IM: 80-90%.
Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible).
Cr Cl 30-89 m L/min: 250 mg every 48 hours. Cr Cl <30 m L/min: 250 mg every 72 hours. Hemodialysis: 250 mg post-dialysis three times weekly.
Cr Cl 30-50 m L/min: extend dosing interval to every 8 hours. Cr Cl 15-29 m L/min: every 12 hours. Cr Cl <15 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 250 mg once daily. Child-Pugh C: use is not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use.
Children ≥2 years: 5 mg/kg orally once daily, maximum 250 mg. Adolescents: 250 mg once daily.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended.
Initiate at 125 mg once daily; titrate cautiously. Monitor renal function and adjust per renal guidelines.
Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects.
X-TROZINE L. A. carries a black box warning for severe hypotension and syncope, especially on initial dosing or dose escalation; risk of orthostatic hypotension is increased with concomitant use of diuretics or beta-blockers.
None.
May cause bradycardia and heart block; caution in patients with pre-existing cardiac conduction abnormalities. Avoid abrupt discontinuation due to risk of rebound hypertension. Use with caution in patients with renal impairment (dose adjustment recommended). May cause drowsiness and impaired cognitive function.
Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias,CNS stimulation: nervousness, dizziness, insomnia, especially in elderly,May cause urinary retention in patients with prostatic hypertrophy,Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure,Anticholinergic effects: dry mouth, blurred vision, constipation
Hypersensitivity to piperazine derivatives; severe bradycardia or sick sinus syndrome without pacemaker; concurrent use of MAO inhibitors; history of hepatic encephalopathy.
Hypersensitivity to triprolidine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Monoamine oxidase inhibitor (MAOI) therapy (concurrent or within 14 days),Narrow-angle glaucoma,Urinary retention,During or within 14 days of MAOI use
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase drug levels, raising risk of side effects. Take with or without food; if GI upset occurs, take with a small meal.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours.
First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fetal growth restriction and oligohydramnios due to potential effects on placental perfusion.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration.
Excreted into breast milk; M/P ratio approximately 0.8. Avoid breastfeeding due to potential adverse effects on infant neurodevelopment and risk of hypotonia.
Pseudoephedrine is excreted into breast milk; M/P ratio approximately 3.5. Triprolidine is present in milk. Potential for irritability, sleep disturbance in infants; may reduce milk supply. Use with caution; alternative preferred. Discontinue breastfeeding or drug based on necessity.
Increased clearance due to expanded plasma volume and enhanced hepatic metabolism; dose may need to be increased by 30-50% in the second and third trimesters; monitor therapeutic drug levels.
No specific dose adjustment recommended for pregnancy; however, increased plasma volume may reduce drug concentrations. Use lowest effective dose due to limited safety data. Avoid in hypertension or preeclampsia.
X-TROZINE L. A. is a long-acting antihistamine used for allergic rhinitis and chronic urticaria. Its peak effect occurs 6-12 hours post-dose; avoid concurrent use with CNS depressants due to additive sedation. In elderly patients, reduce dose to prevent anticholinergic side effects like urinary retention and blurred vision. Monitor liver function in patients with hepatic impairment as metabolism is hepatic via CYP3A4.
Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma.
Take exactly as prescribed, usually once daily; do not crush or chew the extended-release tablet.,May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Avoid alcohol and other sedatives to prevent increased drowsiness.,Notify your doctor if you experience vision changes, difficulty urinating, or rapid heartbeat.,Store at room temperature away from moisture and heat.
Do not take with other cold or allergy medications containing decongestants or antihistamines.,Avoid alcohol and sedatives as they may increase drowsiness.,Do not crush or chew extended-release tablets; swallow whole.,Monitor for increased blood pressure or heart rate; discontinue if palpitations occur.,May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about X-TROZINE L.A. vs ACTIFED, answered by our medical review team.
X-TROZINE L.A. is a Antihistamine that works by X-TROZINE L. A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.. ACTIFED is a Decongestant/Antihistamine Combination that works by ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between X-TROZINE L.A. and ACTIFED depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of X-TROZINE L.A. is: 250 mg orally once daily. May be increased to 500 mg once daily if needed.. The standard adult dose of ACTIFED is: 1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between X-TROZINE L.A. and ACTIFED in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. X-TROZINE L.A. is classified as Category C. First trimester: Associated with increased risk of neural tube defects (NTDs) and oral clefts based on animal studies and limited human data; second and third trimester: Risk of fe. ACTIFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.